Effect of Follicle Size and Follicle-Stimulating Hormone on Ovulation Induction and Embryo Recovery in the Mare

2009 ◽  
Vol 29 (4) ◽  
pp. 213-218 ◽  
Author(s):  
T.J. Cox ◽  
E.L. Squires ◽  
E.M. Carnevale
Keyword(s):  
Ovulation Induction ◽  
Follicle Stimulating Hormone ◽  
Embryo Recovery ◽  
Follicle Size ◽  
Stimulating Hormone

scholarly journals Anti-Mullerian Hormone (AMH) as a Predictor of Ovarian Response to Clomiphene Citrate in Polycystic Ovarian Syndrome

2021 ◽  
pp. 1-7
Author(s):  
Serajoom Munira ◽  
Jesmine Banu ◽  
Shakeela Ishrat ◽  
Mehnaz Mustary Shume ◽  
Muhammad Jasim Uddin ◽  
...  
Keyword(s):  
Ovulation Induction ◽  
Polycystic Ovary ◽  
Clomiphene Citrate ◽  
Follicle Stimulating Hormone ◽  
Negative Relationship ◽  
Poor Response ◽  
Ovarian Response ◽  
Cross Sectional ◽  
Follicle Size ◽  
Stimulating Hormone

Background: Serum Anti-Mullerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS) are two- to threefold higher than in ovulatory women with normal ovaries, corresponding to the two- to threefold increase in the number of small follicles in PCOS. The increased AMH has been hypothesized to reduce follicle sensitivity to follicle stimulating hormone (FSH) and estradiol production, thus preventing follicle selection, resulting in follicular arrest at the small antral phase with failure of dominance. Objective: The study was undertaken to test the hypothesis that high AMH level is associated with poor response to ovulation induction in PCOS women. Methods: This was a cross-sectional comparative study of 50 infertile women with PCOS, grouped into those with AMH level <8 ng/mL and those with AMH level [Formula: see text] 8 ng/mL. All participants received an initial dose of 100 mg/day of clomiphene citrate from 2nd to 6th day of menstrual cycle. Ovarian response (follicle size) was assessed by transvaginal monitoring on 12th day of cycle. Results: A total of 50 women were recruited, of which 4 dropped out. Women with AMH [Formula: see text] 8 ng/mL comprised only 23.91% of the PCOS women. AMH and day 12 follicle size had a statistically significant association. Adjusting for other confounding variables in linear, logarithmic, and logistic analysis, serum AMH had significant negative relationship with follicle size (r = 0.511, p < 0.001). AMH was also positively correlated with serum LH, testosterone and negatively correlated with serum follicle stimulating hormone (FSH), serum TSH and BMI. Conclusion: We observed that higher AMH level women had poor response to ovulation induction compared to women with low AMH level.

scholarly journals Discovery and Preclinical Development of Orally Active Small Molecules that Exhibit Highly Selective Follicle Stimulating Hormone Receptor Agonism

2021 ◽  
Vol 11 ◽  
Author(s):  
Selva Nataraja ◽  
Henry Yu ◽  
Joie Guner ◽  
Stephen Palmer
Keyword(s):  
Ovarian Stimulation ◽  
Hormone Receptor ◽  
Ovulation Induction ◽  
Low Dose ◽  
Intrauterine Insemination ◽  
Follicle Stimulating Hormone ◽  
Controlled Ovarian Stimulation ◽  
Orally Active ◽  
Stimulating Hormone

An orally active follicle stimulating hormone receptor allosteric agonist would provide a preferred treatment for over 16 million infertile women of reproductive age in low complexity methods (ovulation induction-intrauterine insemination) or in high complexity methods (controlled ovarian stimulation-in vitro fertilization). We present two oral follicle stimulating hormone receptor allosteric agonist compounds that have the desired pharmacology, drug metabolism, pharmacokinetics, and safety profile for clinical use. These molecules provide a single agent suitable for ovulation induction-intrauterine insemination or controlled ovarian stimulation-in vitro fertilization that is more convenient for patients and achieves similar preclinical efficacy as rec-hFSH. TOP5668, TOP5300 were evaluated in vitro in Chinese hamster ovary cells transfected with individual glycoprotein receptors measuring cAMP (FSHR, LH/CGR, thyroid stimulating hormone receptor). TOP5668 was found to have solely follicle stimulating hormone receptor allosteric agonist activity while TOP5300 was found to have mixed follicle stimulating hormone receptor allosteric agonist and LHR-AA activity. Both compounds stimulated concentration-dependent increases in estradiol production from cultured rat granulosa cells in the presence or absence of low dose rec-hFSH, while only TOP5300 stimulated testosterone production from rat primary Leydig cells. In pooled human granulosa cells obtained from patients undergoing controlled ovarian stimulation-in vitro fertilization, TOP5300 stimulated 7-fold greater maximal estradiol response than rec-hFSH and TOP5668 was 10-fold more potent than TOP5300. Both TOP5300 and TOP5668 stimulated follicular development in immature rat to the same efficacy as recombinant follicle stimulating hormone. In mice treated with TOP5300, in the presence of low dose of follicle stimulating hormone, there were no differences in oocyte number, fertilization rate, and hatched blastocyst rate in mice with TOP5300 and low dose follicle stimulating hormone vs. reference proteins pregnant mare serum gonadotropin or high dose rec-hFSH. ADME/PK and safety profiles were favorable. In addition, there was no appreciable activity on thyroid hormones by TOP5300 in 14-days toxicological study in rat or dog. The selected lead compound, TOP5300 stimulated a more robust increase in estradiol production from granulosa-lutein cells from women with polycystic ovarian syndrome patient compared to rec-hFSH. Conclusions: Two novel oral FSHR allosteric agonist, TOP5668 and TOP5300, were found to mimic the biological activity of rec hFSH in preclinical studies. Both compounds led to folliculogenesis and superovulation in rat and mice. Specifically, TOP5300 led to a similar number of ovulated oocytes that fertilized and developed into hatched blastocysts in mice when compared to rec-hFSH. The safety profile demonstrated lack of toxicity.

293 SUBCUTANEOUS ADMINISTRATION OF FOLLICLE STIMULATING HORMONE FOR SUPEROVULATION OF HOLSTEIN COWS

2009 ◽  
Vol 21 (1) ◽  
pp. 243 ◽  
Author(s):  
P. W. Farin ◽  
K. M. Dowdall ◽  
J. E. Hicks ◽  
C. E. Farin ◽  
C. S. Whisnant
Keyword(s):  
Repeated Measures ◽  
Animal Health ◽  
Follicle Stimulating Hormone ◽  
Subcutaneous Administration ◽  
Prostaglandin F2α ◽  
Wilcoxon Test ◽  
Holstein Cows ◽  
Embryo Recovery ◽  
Pfizer Animal Health ◽  
Stimulating Hormone

Follicle stimulating hormone (FSH) is usually administered in a series of intramuscular (IM) injections to induce multiple ovulations for embryo production in cattle and other species. The objective of this study was to determine the superovulatory response of dairy cows to subcutaneous (SC) administration of FSH using a reduced number of injections in combination with a progesterone-releasing device. Eighteen non-lactating Holstein cows initially received 25 mg Prostaglandin F2α IM (PGF; Lutalyse; Pfizer Animal Health, Groton, CT, USA) on Day –7. All cows then received an intravaginal progesterone-releasing device (CIDR-B, 1.38 mg progesterone; Pfizer Animal Health) on Day 0, and 100 μg GnRH IM (Cystorelin; Merial Ltd, USA) on Day 2. Cows were randomly assigned to receive a total of 400 mg (20 mL) of FSH (Folltropin-V; Bioniche Animal Health, USA) either by IM injection (IM Group, n = 9 cows) given at 12 h intervals on Days 4 (60 mg, 60 mg), 5 (55 mg, 55 mg), 6 (45 mg, 45 mg) and 7 (40 mg, 40 mg), or by SC injection (SC Group, n = 9 cows) given at 24 h intervals on Days 4 (140 mg), 5 (140 mg) and Day 6 (120 mg). On Day 7, CIDR-B inserts were removed and cows received two 25 mg PGF IM injections given 12 h apart. Cows were artificially inseminated at 12 and 24 h after standing estrus. Blood samples were obtained from all cows at 0, 2, 4, 8, 12, 24, 36, 48, 60, 72, and 84 h after the first FSH injection for determination of serum FSH concentrations. Ovarian follicles and CL were monitored using ultrasonography on Days 4, 7, and 16. Embryos were recovered non-surgically on Day 16 (7 days after estrus). The effects of treatment on follicular response and embryo yield were analyzed by Wilcoxon test, and the response of cows to treatment was analyzed by chi-square test. The effects of treatment on concentrations of serum FSH were analyzed using ANOVA for repeated measures. There was no effect (P > 0.05) of route of FSH administration on the concentrations of serum FSH at any time point. The superovulatory response of cows to treatment, defined as greater than 2 CL per cow, did not differ (P > 0.05) between the IM (77.8%, 7/9 cows) and SC (88.9%, 8/9 cows) Groups. There was also no difference (P > 0.05) between the IM and SC Groups for the number of 5 to 10 mm follicles prior to FSH treatment (mean ± SEM; 0.6 ± 0.2 v. 0.9 ± 0.4), the total number of follicles after FSH treatment (12.4 ± 1.6 v. 12.7 ± 2.2) or the number of CL at embryo recovery (6.4 ± 1.5 v. 10.4 ± 2.1). Similarly, there were no differences (P > 0.05) between the IM and SC Groups for total number of oocytes/embryos (5.6 ± 2.6 v. 13.0 ± 4.3), transferable embryos (Grade 1, 2, 3; 3.0 ± 1.4 v. 6.1 ± 2.9) or Grade 1 embryos (2.9 ± 1.4 v. 4.3 ± 2.5). In conclusion, administration of FSH using 3 SC injections in combination with a progesterone-releasing device was an effective method for superovulation of Holstein cows. Supported by USDA Animal Health Formula Funds and the State of North Carolina.

407 SUPERSTIMULATORY RESPONSE WITH DECREASING DOSES OF FOLLICLE-STIMULATING HORMONE v. A SINGLE DOSE OF FOLLICLE-STIMULATING HORMONE - EQUINE CHORIONIC GONADOTROPIN DURING BREEDING AND NONBREEDING SEASON IN SHEEP

2010 ◽  
Vol 22 (1) ◽  
pp. 360
Author(s):  
M. I. Cueto ◽  
F. Pereyra-Bonnet ◽  
P. Silvestre ◽  
A. E. Gibbons
Keyword(s):  
Single Dose ◽  
Breeding Season ◽  
Recovery Rate ◽  
Follicle Stimulating Hormone ◽  
Ovulation Rate ◽  
Corpora Lutea ◽  
Nonbreeding Season ◽  
Embryo Recovery ◽  
The One ◽  
Stimulating Hormone

The aim of the study was to assess possible variations in superovulatory yields due to different FSH treatments at 2 times of the year. Superovulation and embryo recovery were performed during the breeding (n = 63) andnonbreeding (n = 46) seasons in Merino ewes located at 41°S latitude. Animals were kept under the same conditions, housed outdoors in a sheltered and covered pen, and were fed a liveweight maintenance ration. All animals received 60-mg medroxyprogesterone acetate intravaginal sponges (Progespon®, Syntex, Buenos Aires, Argentina) for 14 days. Ewes were then randomly assigned to 2 different superovulatory treatments: classic (n = 74) and one shot (n = 35) in both seasons. Classic superovulatory treatment consisted of 7 decreasing doses (2 × 48 mg, 2 × 24 mg, 2 × 20 mg, and1 × 16 mg NIH-FSH-P1)ofFSH (Folltropin®-V, Bioniche, Belleville, Ontario, Canada), administered twice daily from 48 h before to 24 h after pessary removal. A dose of eCG (300 IU; Novormon®, Syntex) was administered at progestagen removal. One shot superovulatory treatment consisted of a single dose of FSH (70 mg NIH-FSH-P1) plus 300 UI of eCG injected at pessary withdrawal. Embryo donors were inseminated by laparoscopy with frozen-thawed semen (100 × 106 spz) 12 h after the onset of estrus. Surgical embryo recovery was done on Day 7 after sponge withdrawal and embryos were graded for quality according to morphology (Grade 1 = excellent or good; Grade 2 = fair; Grade 3 = poor; and Grade 4 = dead or degenerated; IETS 1998). A 2 × 2 factorial ANOVA was used to test the main effects (season and superovulatory treatment) and interactions. There were no significant differences in the proportion of responding ewes (>3 corpora lutea), ovulation rate, and recovered Grades 1 to 2 embryos between the breeding and nonbreeding season (Table 1; P > 0.05). However, number of recovered ova/embryos and ova/embryo recovery rate were higher during the breeding season compared with the nonbreeding season, whereas the percentage of nonfertilized ova was lower in the breeding season than in the nonbreeding season (P < 0.05). Analysis of data comparing superovulatory treatments showed that the proportion of responding ewes, ovulation rate, recovered embryos, and recovered Grades 1 to 2 embryos were lower for the one shot treatment than for the classic treatment (P < 0.05). Embryo recovery rate and nonfertilization rate did not differ between treatments (P > 0.05). It was concluded that there was an increase in the number of total recovered ova/embryos during the breeding season compared with the nonbreeding season, although the number of recovered good-quality embryos was not affected. The use of multiple FSH injections produced a higher number of total recovered and viable embryos in Merino sheep than the one shot superovulatory treatment. Table 1.Embryo yields in ewes submitted to superovulation

Ovulation induction by step-down administration of purified urinary follicle-stimulating hormone in patients with polycystic ovarian syndrome

1991 ◽  
Vol 55 (6) ◽  
pp. 1195-1196 ◽  
Author(s):  
Hideki Mizunuma ◽  
Takeshi Takagi ◽  
Kiyohiko Yamada ◽  
Kazumichi Andoh ◽  
Yosito Ibuki ◽  
...  
Keyword(s):  
Ovulation Induction ◽  
Polycystic Ovarian Syndrome ◽  
Follicle Stimulating Hormone ◽  
Step Down ◽  
Ovarian Syndrome ◽  
Stimulating Hormone
Sign in / Sign up

Export Citation Format

Share Document